Phase I Trial of 8-Chloroadenosine and Venetoclax in Relapsed/Refractory AML
A phase I trial is underway to evaluate the safety and efficacy of 8-chloroadenosine combined with venetoclax in relapsed/refractory acute myeloid leukemia patients.
Asset / Drug
Drug and asset intelligence for Venetoclax with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.